Korean Circ J.  2010 Jul;40(7):348-351. 10.4070/kcj.2010.40.7.348.

Fatal Renal Bleeding in a Patient Treated With Aggressive Antithrombotic Therapy After Recurrent Coronary Stent Thrombosis

• Moon J
• Lee SH
• Yang WI
• Ko YG
• Han WK
• Jang Y

• KMID: 2225180
• DOI: http://doi.org/10.4070/kcj.2010.40.7.348

Abstract

Triple antiplatelet therapy has been known to be superior to the conventional dual regimen for preventing stent thrombosis after coronary stenting, and the addition of oral anticoagulation to antiplatelet therapy is also considered an option. However, the risks and benefits of a triple antiplatelet regimen plus additional oral anticoagulation must be taken into account. Here, we report a case of fatal renal bleeding in a patient treated with triple antiplatelet plus oral anticoagulant therapy for the prevention of recurrent stent thrombosis.

Keyword

Drug-eluting stents; Coronary thrombosis; Drug combinations

MeSH Terms

Coronary Thrombosis
Drug Combinations
Drug-Eluting Stents
Hemorrhage
Humans
Risk Assessment
Stents
Thrombosis
Drug Combinations

Figure

• 

  Fig. 1 Coronary angiographies taken at each event (RCA). A: stent thrombosis and partial obstruction in the RCA (arrow) in July 2008. B: RCA revascularized by thrombosuction and implantation of new stents. C: recurrent stent thrombosis and partial obstruction (arrow) in August 2008. D: lesion revascularized by thrombosuction. E: recurrent stent obstruction (arrow) in September 2008. F: lesion treated by repeated thrombosuction and new stent implantation.

• 

  Fig. 2 Abdominal CT. Massive hemorrhage in left kidney (arrow).

Reference

1. Honda Y, Fitzgerald PJ. Stent thrombosis: an issue revisited in a changing world. Circulation. 2003. 108:2–5.

2. Gurbel PA, DiChiara J, Tantry US. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. Am J Cardiol. 2007. 100:18M–25M.

3. Jaffe R, Strauss BH. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives. J Am Coll Cardiol. 2007. 50:119–127.

4. Manzano-Fernandez S, Marin F, Pastor-Perez FJ, et al. Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting. Chest. 2009. 135:983–990.

5. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008. 134:559–567.

6. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol. 2009. 53:1101–1109.

7. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009. 157:733–739.

8. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008. 51:1181–1187.

9. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007. 100:1103–1108.

10. Jeon DS, Yoo KD, Park CS, et al. The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J. 2010. 40:10–15.

11. Yang TH, Kim DI, Kim JY, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J. 2009. 39:462–466.

12. Francescone S, Halperin JL. "Triple therapy" or triple threat?: balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. J Am Coll Cardiol. 2008. 51:826–827.

13. Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008. 102:1618–1623.

14. Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008. 51:818–825.

15. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest. 2006. 130:1823–1827.

16. Grantham JJ. Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med. 2008. 359:1477–1485.